Abiopharma

🔍 Versant Venture Capital VI, L.P. (Executive)

Company: LENZ Therapeutics, Inc. (LENZ)

Report Date: 2025-08-22

Detailed Transactions and Holdings:

• Sold 20,493 shares of Common Stock at $40.0297 per share (Direct)
  Date: 2025-08-22 | Code: S | equity_swap_involved: false | shares_owned_after: 1,379,727.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 10,076 shares of Common Stock at $40.0297 per share (Direct)
  Date: 2025-08-22 | Code: S | equity_swap_involved: false | shares_owned_after: 952,802.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 5,668 shares of Common Stock at $40.5899 per share (Direct)
  Date: 2025-08-22 | Code: S | equity_swap_involved: false | shares_owned_after: 1,374,059.00 | transaction_form_type: 4 | Footnotes: F4, F2
• Sold 2,809 shares of Common Stock at $40.5899 per share (Direct)
  Date: 2025-08-22 | Code: S | equity_swap_involved: false | shares_owned_after: 949,993.00 | transaction_form_type: 4 | Footnotes: F4, F2
• Sold 50,270 shares of Common Stock at $39.5255 per share (Direct)
  Date: 2025-08-25 | Code: S | equity_swap_involved: false | shares_owned_after: 1,323,789.00 | transaction_form_type: 4 | Footnotes: F5, F2
• Sold 24,760 shares of Common Stock at $39.5255 per share (Direct)
  Date: 2025-08-25 | Code: S | equity_swap_involved: false | shares_owned_after: 925,233.00 | transaction_form_type: 4 | Footnotes: F5, F2
• Sold 2,149 shares of Common Stock at $39.9212 per share (Direct)
  Date: 2025-08-25 | Code: S | equity_swap_involved: false | shares_owned_after: 1,321,640.00 | transaction_form_type: 4 | Footnotes: F6, F2
• Sold 1,058 shares of Common Stock at $39.9212 per share (Direct)
  Date: 2025-08-25 | Code: S | equity_swap_involved: false | shares_owned_after: 924,175.00 | transaction_form_type: 4 | Footnotes: F6, F2
• Sold 43,978 shares of Common Stock at $38.9744 per share (Direct)
  Date: 2025-08-26 | Code: S | equity_swap_involved: false | shares_owned_after: 1,277,662.00 | transaction_form_type: 4 | Footnotes: F7, F2
• Sold 21,661 shares of Common Stock at $38.9744 per share (Direct)
  Date: 2025-08-26 | Code: S | equity_swap_involved: false | shares_owned_after: 902,514.00 | transaction_form_type: 4 | Footnotes: F7, F2
• Sold 3,465 shares of Common Stock at $39.5022 per share (Direct)
  Date: 2025-08-26 | Code: S | equity_swap_involved: false | shares_owned_after: 1,274,197.00 | transaction_form_type: 4 | Footnotes: F8, F2
• Sold 1,707 shares of Common Stock at $39.5022 per share (Direct)
  Date: 2025-08-26 | Code: S | equity_swap_involved: false | shares_owned_after: 900,807.00 | transaction_form_type: 4 | Footnotes: F8, F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-08-22 | Code: H | nature_of_ownership: See Footnote | shares_owned_after: 842,162.00 | Footnotes: F9

Footnotes:

• F1: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $39.5085 to $40.4616, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
• F2: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.
• F3: These shares are held by Versant Venture Capital VII, L.P. ("VVC VII"). Versant Ventures VII GP-GP, LLC ("VV VII GP") is the sole general partner of Versant Ventures VII GP, L.P. ("VV VII") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.
• F4: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $40.50 to $40.8819, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
• F5: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $38.815 to $39.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (5) to this Form 4.
• F6: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $39.81 to $40.015, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (6) to this Form 4.
• F7: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $38.50 to $39.485, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (7) to this Form 4.
• F8: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $39.49 to $39.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (8) to this Form 4.
• F9: These shares are held by Versant Vantage II, L.P. ("VV II"). Versant Vantage II GP-GP, LLC ("VV II GP-GP") is the sole general partner of Versant Vantage II GP, L.P. ("VV II GP") and VV II GP is the sole general partner of VV II. Each of VV II GP-GP and VV II GP may be deemed to share voting, investment and dispositive power over the shares held by VV II and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.